Psoriasis

M351-0056 is an orally active VISTA agonist with a K_d value of 12.60 μM. M351-0056 inhibits the activation of the JAK2-STAT2 pathway, reduces the phosphorylation levels of JAK2 and STAT2, and regulates type I interferon (IFN-I) and non-canonical NF-κB pathways. M351-0056 decreases the levels of cytokines (IFN-γ, IL-17A, TNF-α, IL-2 and IL-1β). M351-0056 improves imiquimod (HY-B0180)-induced psoriasis-like skin inflammation, reduces autoantibody levels, kidney damage and immune cell expansion in mice susceptible to chronic graft-versus-host disease and lupus, and delays the progression of systemic lupus erythematosus. M351-0056 can be used in research related to psoriasis-like dermatitis and systemic lupus erythematosus.

JTE-151 is an orally active, selective RORγ antagonist with IC₅₀ values of 20.6 nM, 41.8 nM and 32.2 nM against hRORγ, rRORγ and mRORγ, respectively. JTE-151 reduces the production of IL-17. JTE-151 alleviates paw swelling and bone destruction in arthritis models. JTE-151 can be used in research related to rheumatoid arthritis, collagen-induced arthritis, experimental autoimmune encephalomyelitis, psoriasis, multiple sclerosis and inflammatory bowel disease.

Icotrokinra (JNJ-77242113) hydrochloride is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra hydrochloride inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC₅₀=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC₅₀ of 18.4 pM. Icotrokinra hydrochloride exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra hydrochloride can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease.

Lecankitug (LZM-012) is a humanized IgG1κ monoclonal antibody targeting IL-17A/F. Lecankitug exerts immunosuppressive and anti-inflammatory activities. Lecankitug can be used in the research of autoimmune and inflammatory diseases, such as psoriasis, ankylosing spondylitis, and rheumatoid arthritis.

Flt-3L-Ig (hum/hum) (hFlt3L) is a Flt3 ligand. Flt-3L-Ig (hum/hum) enhances the release of inflammatory cytokines from myeloid cells and dendritic cells in BRGSF-CBC mice induced by OKT3. Flt-3L-Ig (hum/hum) increases the release of IL-2, CCL2 and CXCL10 in an OKT3-dependent manner. Flt-3L-Ig (hum/hum) can be used in studies related to cytokine release syndrome. Flt-3L-Ig (hum/hum) can be used in studies related to psoriasis-like skin inflammation.

Netakimab (BCD-085) is a humanized IgG1κ monoclonal anti-IL-17 antibody that binds to and blocks IL-17 and IL-17A activity, including reduction of downstream IL-6 production. Netakimab can be used for the research of moderate-to-severe plaque psoriasis, ankylosing spondylitis, and COVID-19 with cytokine release syndrome. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

Serlopitant (VPD-737) is an orally active Neurokinin 1 receptor antagonist. Serlopitant inhibits pruritus signal transduction via NK receptors in spinal neurons and brain regions, and blocks the efferent function of substance P in the skin. Serlopitant can be used in research related to chronic pruritus, prurigo nodularis, and pruritus associated with psoriasis.

MK-0873 is a selective phosphodiesterase-4 (PDE4) inhibitor with an IC₅₀ value of < 38 nM. MK-0873 inhibits LPS-induced TNF-α production. MK-0873 suppresses bronchoconstriction. MK-0873 is applicable to research related to chronic obstructive pulmonary disease, plaque psoriasis and asthma.

Icotrokinra (JNJ-77242113) acetate is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra acetate inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC₅₀=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC₅₀ of 18.4 pM. Icotrokinra acetate exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra acetate can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease.

TCB-32 (Compound I-1) is a FGFR1 agonist with an EC₅₀ of 0.88  μM. TCB-32 significantly increases cell proliferation through activating FGFR1 signaling pathway as bFGF and its downstream ERK1/2 with excellent thermal stability. TCB-32 can replace bFGF in serum-free cell culture media. TCB-32 can be used for tissue repair and wound healing related diseases like psoriasis and eczema research.

CJM112 is a fully human IgG1/κ monoclonal antibody inhibitor targeting IL-17A, which binds to IL-17A and the IL-17AF heterodimer with high affinity, with K_D values of 5.7 pM and <11 pM, respectively. CJM-112 exerts anti-inflammatory effects by neutralizing IL-17A, and reduces the Psoriasis Area and Severity Index in a time- and dose-dependent manner. CJM-112 also exhibits anti-inflammatory activity and improves disease severity in studies of hidradenitis suppurativa. CJM-112 shows favorable biosafety and tolerability. CJM-112 can be used in studies related to psoriasis and hidradenitis suppurativa.

Methotrexate-d₃ diammonium is the deuterated-labeled Methotrexate (HY-14519). Methotrexate (Amethopterin; CL14377; WR19039) is an orally active antifolate (Antifolate). Methotrexate inhibits dihydrofolate reductase (DHFR), blocks tetrahydrofolate production, suppresses purine/pyrimidine synthesis and transmethylation, and causes intracellular accumulation of AICAR. Methotrexate promotes extracellular adenosine release, regulates the cytokine network, and inhibits the alarmin function of HMGB1. Methotrexate induces apoptosis and cytotoxicity, upregulates the expression of iNOS and COX-2, suppresses hippocampal neurogenesis, and induces pulmonary fibrosis. Methotrexate is used in the research of various immune and inflammation-related diseases such as arthritis, psoriasis, systemic lupus erythematosus, as well as pulmonary fibrosis and breast cancer.

TAVO101 is a humanized anti-TSLP antibody with an EC₅₀ of 0.19 nM against hTSLP. TAVO101 inhibits STAT5 activation and CCL17 release. TAVO101 carries Fc region mutations that enhance its binding to FcRn while reducing its binding to FcγRI, FcγRIIIA and C1q, thereby attenuating effector functions. TAVO101 reduces the levels of inflammatory markers, cell infiltration and histopathological damage in preclinical models of asthma, psoriasis and atopic dermatitis. TAVO101 can be used for research related to asthma, psoriasis and atopic dermatitis.

Methotrexate monohydrate (Amethopterin monohydrate; CL14377 monohydrate; WR19039 monohydrate) is an orally active antifolate (Antifolate). Methotrexate monohydrate inhibits dihydrofolate reductase (DHFR), blocks tetrahydrofolate production, suppresses purine/pyrimidine synthesis and transmethylation, and causes intracellular accumulation of AICAR. Methotrexate monohydrate promotes extracellular adenosine release, regulates the cytokine network, and inhibits the alarmin function of HMGB1. Methotrexate monohydrate induces apoptosis and cytotoxicity, upregulates the expression of iNOS and COX-2, suppresses hippocampal neurogenesis, and induces pulmonary fibrosis. Methotrexate monohydrate is used in the research of various immune and inflammation-related diseases such as arthritis, psoriasis, systemic lupus erythematosus, as well as pulmonary fibrosis and breast cancer.

HB-0043 is a IL-17A and IL-36R antagonist. HB-0043 blocks IL-17A- and IL-36R-mediated signaling pathways, inhibits the production of inflammatory cytokines, and reduces the secretion of pro-inflammatory cytokines IL-6 and IL-8. HB-0043 alleviates skin thickening and inflammatory responses in oxazolone-induced and Imiquimod (HY-B0180)-induced skin reaction mouse models. HB-0043 is applicable for the research of atopic dermatitis and psoriasis.

Nomelcitinib is a TYK2 inhibitor that modulates the IL23 signaling pathway. Nomelcitinib is used for research on multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, psoriasis, psoriatic arthritis, Crohn's disease, Sjögren's syndrome, and scleroderma.

Vibozilimod (SCD-044) is an oral S1P1/EDG1 receptor-selective agonist with an EC₅₀ of <1 nM. Vibozilimod promotes S1P1/EDG1 receptor internalization, inhibits lymphocyte migration, induces lymphopenia and reduces lymphocyte counts. Vibozilimod is used for the research of inflammatory diseases such as psoriasis and atopic dermatitis.

(±)-Methotrexate ((±)-Amethopterin; (±)-CL14377; (±)-WR19039) is the racemate of Methotrexate (HY-14519). Methotrexate is an orally active antifolate (Antifolate). Methotrexate inhibits dihydrofolate reductase (DHFR), blocks tetrahydrofolate production, suppresses purine/pyrimidine synthesis and transmethylation, and causes intracellular accumulation of AICAR. Methotrexate promotes extracellular adenosine release, regulates the cytokine network, and inhibits the alarmin function of HMGB1. Methotrexate induces apoptosis and cytotoxicity, upregulates the expression of iNOS and COX-2, suppresses hippocampal neurogenesis, and induces pulmonary fibrosis. Methotrexate is used in the research of various immune and inflammation-related diseases such as arthritis, psoriasis, systemic lupus erythematosus, as well as pulmonary fibrosis and breast cancer.

Envudeucitinibum (Envudeucitinib; ESK-001) hydrochloride is an orally active and selective TYK2 allosteric inhibitor with an IC₅₀ range of 104-149 nM. Envudeucitinibum hydrochloride blocks JH1 catalytic activity by specifically binding to the JH2 domain of TYK2, thereby inhibiting downstream signaling pathways. Envudeucitinibum hydrochloride is used for research on plaque psoriasis, systemic lupus erythematosus, and other immune-mediated diseases.

AhR/PDE4 modulator-1 is a AhR/PDE4D dual-target modulator, with an AhR agonistic EC₅₀ of 0.11 μM and a PDE4D inhibitory IC₅₀ of 2.12 μM. AhR/PDE4 modulator-1 activates the AhR-CYP1A1 signaling pathway, promotes AhR nuclear translocation, and upregulates downstream CYP1A1; it inhibits PDE4D activity, elevates intracellular cAMP levels, and activates the downstream cAMP-PKA-CREB signaling pathway. Topical administration of AhR/PDE4 modulator-1 exerts anti-inflammatory effects in the Imiquimod (HY-B0180)-induced psoriasis-like mouse model, alleviates epidermal hyperplasia and inflammatory infiltration, and suppresses the expression of IL-17A/F. AhR/PDE4 modulator-1 can be used in research related to psoriasis.